
Novo Nordisk's partnership with OpenAI will “help the company bring new and better treatment options to patients faster,” the Danish pharmaceutical company announced on Tuesday.
The collaboration will allow Novo Nordisk to apply advanced AI to analyse complex datasets, identify potential drugs, and cut the time between research and patient access.